期刊
ANTIBIOTICS-BASEL
卷 10, 期 12, 页码 -出版社
MDPI
DOI: 10.3390/antibiotics10121475
关键词
antimicrobial stewardship; ceftazidime; avibactam; meropenem; vaborbactam; cefiderocol; place in therapy; multidrug resistant organisms; carbapenemase-producing Enterobacterales; carbapenem-resistant Acinetobacter baumannii
The global spread of antimicrobial resistance poses a major threat to global health and development, with infections by MDRO often leading to unfavorable outcomes. The emergence of new antimicrobial agents with potent activity against MDROs requires careful and strategic utilization to improve patient outcomes, especially in environments with high prevalence of MDROs and among critically ill populations.
The worldwide propagation of antimicrobial resistance represents one of the biggest threats to global health and development. Multi-drug-resistant organisms (MDROs), including carbapenem-resistant non-fermenting Gram-negatives and Enterobacterales, present a heterogeneous and mutating spread. Infections by MDRO are often associated with an unfavorable outcome, especially among critically ill populations. The polymyxins represented the backbone of antibiotic regimens for Gram-negative MDROs in recent decades, but their use presents multiple pitfalls. Luckily, new agents with potent activity against MDROs have become available in recent times and more are yet to come. Now, we have the duty to make the best use of these new therapeutic tools in order not to prematurely compromise their effectiveness and at the same time improve patients' outcomes. We reviewed the current literature on ceftazidime/avibactam, meropenem/vaborbactam and cefiderocol, focusing on antimicrobial spectrum, on the prevalence and mechanisms of resistance development and on the main in vitro and clinical experiences available so far. Subsequently, we performed a step-by-step construction of a speculative algorithm for a reasoned prescription of these new antibiotics, contemplating both empirical and targeted use. Attention was specifically posed on patients with life-risk conditions and in settings with elevated prevalence of MDRO.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据